

Innovation in Plasma Technology: The NexSys PCS[®] Advantage

IPFA Meeting, Leuven, Belgium 12. February 2026

Alexander Steffan
Vice President, Global Marketing and Strategy

COL-COPY-002667-IE(AA)


HAEMONETICS[®]

Haemonetics – The Pioneer in Blood Separation and Collection

History of Haemonetics – 55 years of innovation

- In **1960's** Dr. Cohn and Jack Latham worked together for ADL developing a blood centrifuge. Jack Latham invented **the first disposable centrifuge bowl** and related systems for blood processing.
- In **1968**, The first “Latham Bowl” was licensed to Abbott Laboratories for manufacturing.
- In **1971 Jack Latham** decided to found his own company. The **Haemonetics history begins**.
- In **1980's** Haemonetics introduces the **first automated plasmaphereses device** (PCS®) and the **first intraoperative cell salvage device** to the market (Cell Saver®).
- In **1990's** Haemonetics introduce the **first multicomponent device** (MCS+).
- **Continuous innovation** until today in automated cell processing technologies.

The Latham Bowl revolutionizes blood collection process.



First disposable bowl prototype molded in Jack Latham's family kitchen.



Latham Bowl developed by J. Latham in the 1960s.

Haemonetics – A Strong and Reliable Partner for 55 Years.

Haemonetics FY 25*:

Employees > 3000

Products in > 90 countries

Annual Revenue > 1,4 billion US \$

Plasma is a key business pillar, contributing 40% of total FY25 revenue.



Diversified portfolio

(high-level revenue figures):

- 40 % Plasma business
- 20 % Blood center business
- 40 % Hospital (IVT and Blood Management Technologies)

Long-term reliability and stability ensured through diversified portfolio and regional outreach.

Continuous Innovation: Evolution of NexSys PCS® Device from Genesis to Today

NexSys PCS®

Technology

YES® Technology*

Persona® Technology*

Device 360*

Express® Plus
0625Q-00

RDU*¹

Approval

FDA approval

CE Europe



Software

1.3.0

1.3.1

1.3.2

1.4.2

1.4.3

1.4.4

1.5.3

1.5.4

1.5.6

Improvement

- Increase Plasma Yield
- Reduce Anticoagulant

- Personalized Nomogram
- Individualized plasma donations

- Fleet control
- Device status

- 15% Shorter procedure time**
- Greater center efficiency*
- Improved donor experience

¹Remote device update


* Persona, YES, Device 360* Center 360*, RDU* is not available out of the USA (2026). **HAEMONETICS®**
** data on file

Strong investments by Haemonetics in scientific evidence and peer-reviewed clinical trials.

Publications in Plasma Collection Over the Last Five Years:

1. [The invisible lifeline: Intricacies of the global plasma supply.](#)
Hartmann J, Stowell SR, Klein HG. Am J Hematol. 2024 Dec;99(12):2261-2265. doi: 10.1002/ajh.27499; Epub 2024 Oct 6. PMID: 39370623.
2. [Large-scale real-world data analysis of source plasma collections using a novel technology-enabled nomogram.](#)
Hellman E, Manukyan Z, Mkhitarian K, Heidarsdottir K, Ragusa MJ, Hartmann J. Transfusion. 2023 Dec;63(12):2256-2264. doi: 10.1111/trf.17579. Epub 2023 Oct 15. PMID: 37839089
3. [Timing of hypotensive adverse events in U.S. source plasma donors: Exploratory analysis from the IMPACT trial.](#)
Hartmann J, Ragusa MJ, Manukyan Z, Popovsky MA. Transfus Apher Sci. 2022 Dec;61(6):103470. doi: 10.1016/j.transci.2022.103470. Epub 2022 May 28. PMID: 35667962
4. [Experience with COVID-19 convalescent plasma provides vital guidance to future pandemics.](#)
Hartmann J, Bloch EM, Burnouf T. Transfusion. 2022 Mar;62(3):681-684. doi: 10.1111/trf.16810. Epub 2022 Jan 30. PMID: 35098540.
5. [Repeat donation and deferral rates in US source plasma donors: Exploratory analysis from the IMPACT trial.](#)
Hartmann J, Ragusa MJ, Burchardt ER, Manukyan Z, Popovsky MA, Leitman SF. Transfusion. 2023 Oct;61(10):2849-2854. doi: 10.1111/trf.16610. Epub 2021 Jul 26. PMID: 34309028 Clinical Trial.
6. [Supply and demand for plasma-derived medicinal products - A critical reassessment amid the COVID-19 pandemic.](#)
Hartmann J, Klein HG. Transfusion. 2020 Nov;60(11):2748-2752. doi: 10.1111/trf.16078. Epub 2020 Sep 9. PMID: 32856742.

Since 2020, Haemonetics has authored more than >40 scientific publications.



The NexSys PCS[®] device is in active use across multiple countries worldwide.






NexSys PCS Device Availability Overview:

| | |
|-------------------|---------------|
| Languages: | 15 |
| Countries: | 23 |
| Donation Centers: | > 500 |
| Devices: | > 20,000 |
| Donations: | > 150 million |

Bi-directional transmission of relevant donor and procedure data between NexSys PCS® Device and BECS-System.

- Plasma Target
- Donor Picture
- Allergic events
- Collection history
- Hematocrit
-



- Actual Plasma
- Total collected product
- Date & Time of collection
- RBC loss
- Citrate & Saline used
-


Procedure Smith, Jo...

| Plasma Target | Samples | Donor ID | | | | | | | | | | |
|--|---------|---------------|---------------------------------|------|-----------|----|------------|-----------|----|------------|---|--|
| 750 ml | 0 / 3 | 00004012 | | | | | | | | | | |
| Hematocrit | Height | Government ID | | | | | | | | | | |
| 45 % | 71 in | 012345 | | | | | | | | | | |
| Blood Pressure | Protein | Collection # | John Smith 12/15/1984 | | | | | | | | | |
| 80/120 | 10.0 | 235402 | | | | | | | | | | |
| Exceptions 10/02/2019 Allergic Eve... More | | | | | | | | | | | | |
| History <table border="1"> <thead> <tr> <th>Collected</th> <th>Time</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>1: 750 ml</td> <td>43</td> <td>10/02/2019</td> </tr> <tr> <td>2: 880 ml</td> <td>40</td> <td>09/10/2019</td> </tr> </tbody> </table> | | Collected | Time | Date | 1: 750 ml | 43 | 10/02/2019 | 2: 880 ml | 40 | 09/10/2019 | Lifetime 3 Iodine Right Arm Preferred | |
| Collected | Time | Date | | | | | | | | | | |
| 1: 750 ml | 43 | 10/02/2019 | | | | | | | | | | |
| 2: 880 ml | 40 | 09/10/2019 | | | | | | | | | | |

NexSys PCS® Device User Interface

Bidirectional Connectivity of NexSys PCS® to Various BECS Systems Demonstrates a 100% Success Rate.

Haemonetics has a proven record of successfully connecting NexSys PCS devices to multiple BECS.



HAEMONETICS®

Fully connected customers:

| Provider | BECS | Customers | Countries |
|--------------------------------|---|--------------|----------------|
| ebps | BPMS | 2 customers | Germany |
| inlog | EdgeBlood | 1 customer | Germany |
| Steiner medical software | Amadeus | 1 customer | Czech Republic |
| | CIS | 1 customer | Czech Republic |
| Miroslav Danihel GetOne s.r.o. | HEMO ZeusCommunicator | 1 customer | Czech Republic |
| TIS Brno | T.I.S. | 2 customers | Czech Republic |
| Haemonetics | NexLynk | Multiple | USA&Canada |
| Haemonetics | elynx (indirect connectivity via handhelds) | > 10 centers | Italy |

Connectivity in progress:

3 customers in 3 countries

HAEMONETICS®

Haemonetics offers a wide range of disposables for use on the NexSys PCS[®] Device (CE/MDR approved).

3 Bowls




Optimized for plasma quality and speed variability

7 unbundled Sets



Increased donor safety offering sets with
+/- correct connect
+/- drip chamber

6 Pre-connected Sets



Multiple options for a wide range of applications:
+/- vacuum sampling adapter
+/- air management bag
+/- drip chamber
saline with luer lock or spike
different bowl option

7 Bags/bottles:



Broad offering for a wide range of collection options:
+/- saline compensation
+/- vacuum sampling adapter
Saline with luer lock or spike

*Depending on your country, more or different consumables might be available. Please check with your local Haemonetics representative.

High Flexibility Enabled by NexSys PCS® Configuration and Consumables

Plasma quality
Donor comfort

Consumables:

- **HS** bowl
- Pre-connected sets

NexSys PCS Settings:

- Standard software
- Reduced ECV
- Reduced draw/return speed
- Saline usage after every cycle or halfway

Center efficiency
Donor satisfaction

Consumables:

- **Q** bowl
- Single consumables

NexSys PCS Settings:

- Express® Plus software
- Smart Last Cycle
- Saline on demand

Gradual
configuration/setting
possible

Lower cell count
Little longer procedure times
Plasma for transfusion


Fastest procedure times
Higher cell count
Plasma for fractionation

NexSys PCS[®] Device Improved Donor Safety and Compliance compared to PCS[®]2



Increasing donor safety

- Minimizing the risk of connecting incorrect solutions with **correct connect** sets.
- Minimizing the risk of over- or underdosing sodium citrate controlled by **AC weigher** and number of pump turns.
- Minimization risk of over- and underdraws through connected devices.



Increasing quality and conformity

- Open bidirectional BECS connectivity for paperless, digital documentation and guided workflows
- Avoidance of time-consuming QA paperwork
- Automated lot and operator approval

Haemonetics supports NexSys PCS® customers with a broad Technical and Application Service organization.



Certified Technical & Application Service Support:

- Haemonetics Central Europe has more than 70 fully trained Technical and Application Service Specialists.
- Support capacity can be significantly increased within weeks through established third-party Technical Service partnerships.
- Cross-border support is available as needed.

Haemonetics — your reliable partner in plasma collection innovation, today and in the future.

2030

2040

2050

and beyond

- Fleet management
- Software improvements
- Disposable upgrades

We are your partner for now
and in the future

A Proud History of Innovation Continues!

Thanks for your attention